http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 10:48:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++144++++++++IONIS+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+BERTHELSEN+SPENCER+R/26581011.html si-local-file:///var/storage/secattach/20260601/26581011.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++IONIS+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+BERTHELSEN+SPENCER+R/26581011.html Mon, 01 Jun 2026 10:48:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++144++++++++IONIS+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+BERTHELSEN+SPENCER+R/26581011.html si-local-file:///var/storage/secattach/20260601/26581011.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++IONIS+PHARMACEUTICALS++++++++++++++++++Filed+by%3A+BERTHELSEN+SPENCER+R/26581011.html Mon, 01 Jun 2026 10:48:00 -0400 IONS O.00134870 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Ionis+Pharmaceuticals+%28IONS%29/26578818.html <p>H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $125.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).</p><p>The analyst commented: "GlaxoSmithKline's B-Well 1/2 Phase 3 studies delivered a 19% functional cure rate in the overall chronic hepatitis B (CHB) population with baseline hepatitis B surface antigen (HBsAg) ≤3,000 IU/mL vs. 0% on standard of care, and a 26% functional cure rate in the lower-HBsAg subgroup ≤1,000 IU/mL vs. 0%. Ionis retains 10-12% tiered royalties plus $150M of remaining regulatory/sales milestone eligibility while GSK funds development, regulatory work, and commercialization. Given FDA Priority Review; a PDUFA date of October 26, 2026; http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Ionis+Pharmaceuticals+%28IONS%29/26578818.html Mon, 01 Jun 2026 06:57:19 -0400 IONS http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IONIS+PHARMACEUTICALS+++++For%3A+May+28/26564488.html si-local-file:///var/storage/secattach/20260528/26564488.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IONIS+PHARMACEUTICALS+++++For%3A+May+28/26564488.html Thu, 28 May 2026 12:41:00 -0400 IONS O.00134870 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IONIS+PHARMACEUTICALS+++++For%3A+May+28/26564488.html si-local-file:///var/storage/secattach/20260528/26564488.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IONIS+PHARMACEUTICALS+++++For%3A+May+28/26564488.html Thu, 28 May 2026 12:41:00 -0400 IONS O.00134870 http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Press+Releases/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344 http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html <p class="bwalignc"> – <i>Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care –</i> </p><p class="bwalignc"> – <i>49% of bepirovirsen recipients achieved a surface antigen level of ≤100 IU/mL one year after end of treatment in exploratory analysis –</i> </p><p class="bwalignc"> – <i>A loss in surface antigen is associated with a significant reduction in risk of liver cancer –</i> </p><p class="bwalignc"> – <i>Over 240 million people worldwide live with chronic hepatitis B –</i> </p> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ionis.com%2F&amp;esheet=54543079&amp;newsitemid=20260527201380&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=fa335614fdfca5c7b4af2695f78f8c1d" shape="rect">Ionis Pharmaceuticals, Inc.</a> (Nasdaq: IONS) partner http://www.streetinsider.com/Business+Wire/Ionis+partner+GSK+announces+bepirovirsen+achieves+unprecedented+functional+cure+rates+with+potential+to+redefine+treatment+for+chronic+hepatitis+B/26560149.html Thu, 28 May 2026 04:45:00 -0400 A.06822034 IONS O.00134870 O.20026344